Spyre Therapeutics Inc. Common Stock vs Warner Music Group Corp — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Warner Music Group Corp trades at $29.15 (market cap $15.12B). The key difference: Warner Music Group Corp is far larger — about 2× Spyre Therapeutics Inc. Common Stock's market cap, and Warner Music Group Corp pays a 2.77% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Warner Music Group Corp for 97 Days on average.
| SYRE | WMG | |
|---|---|---|
Market Cap | $7.52B | $15.12B |
Volume | 1,441,031 | 1,464,172 |
Sector | Health | Media |
52-Week High | $108.92 | $34.72 |
52-Week Low | $22.18 | $23.65 |
Typical Hold Time | 0 Days | 97 Days |
Enterprise Value | $6.52B | $19.42B |
Dividend Yield | — | 2.77% |
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Warner Music Group (WMG) trades at $28.91, up 0.91% on the day, with a bullish technical outlook and strong analyst consensus. Recent earnings show revenue growth to $6.71B in 2025, with net income of $365M, while Q3 2026 results are pending. The stock benefits from positive sentiment around AI partnerships and streaming growth, though it faces margin pressure from rising costs.
The investment outlook is positive, supported by a $39.50 analyst price target and institutional buying. Key opportunities include AI-driven content curation and market share gains, but risks involve competitive pressures and execution challenges amid leadership changes. The stock's current valuation at a P/E of 23.12 appears reasonable given growth prospects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →